M&A Deal Summary |
|
|---|---|
| Date | 2019-10-31 |
| Target | MDM |
| Sector | Life Science |
| Buyer(s) | Neopharmed Gentili |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2011 |
| Sector | Life Science |
| Revenue | 192M EUR (2017) |
Neopharmed Gentili is an Italian pharmaceutical group focused on the research, development, production, and distribution of medicines in many therapeutic areas such as vascular and cardio-metabolic areas, pneumatological areas, antibiotics, OTCs, and supplements. Neopharmed Gentili was founded in 2011 and is based in Milan, Italy.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: Italy M&A | 1 of 1 |
| Year: 2019 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-06-27 |
European Orladeyo Berotralstat business
Durham, North Carolina, United States European Orladeyo Berotralstat business offers a focused portfolio and infrastructure dedicated to the prevention of hereditary angioedema attacks. European Orladeyo Berotralstat business is based in Durham, North Carolina. |
Buy | $264M |
